Sign inJoin waitlistJoin the waitlist

Lawrence Fong

Science Director, Immunotherapy Integrated Research Center · University of Washington School of Medicine

Credentials: · · · · ·

History

Immunotherapy Integrated Research Center · University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of the Pacific
Present

Medical Oncology
1995–1997
Internal Medicine
University of Washington School of Medicine
1992–1995
Stanford University School of Medicine
1988–1992
Columbia University
1984–1988

Research

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Nature · 2018 · 4,366 citations
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
New England Journal of Medicine · 2017 · 2,802 citations
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Cell · 2019 · 1,152 citations

Eric Small
43 papers
David Oh
23 papers · 3 as a fellow
Terence Friedlander
21 papers · 2 as a fellow
CR
Charles Ryan
18 papers
Rahul Aggarwal
18 papers
AC
Alexander Cheung
14 papers
Edgar Engleman
14 papers
Brian Rini
11 papers
Bridget Keenan
11 papers · 2 as a fellow
Toni Choueiri
10 papers
Xiaolin Wei
10 papers · 1 as a resident
Jonathan Chou
9 papers · 3 as a fellow

Grants

UCSF Specialized Programs of Research Excellence (SPOREs) in Prostate Cancer
National Cancer Institute · P50
Project lead · $1.5M · University of California, San Francisco
2024–2029
Determinants of Response to Cancer Immunotherapy
National Cancer Institute · R35
Contact PI · $5.8M · Fred Hutchinson Cancer Center
2021–2028
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $366.5K · University of California, San Francisco
1999–2028
Precision Targeting of T Cell Cytotoxicity with PET
National Cancer Institute · R01
PI · $1.8M · University of California, San Francisco
2021–2026

Clinical trials

Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
Principal investigator · Withdrawn · Phase 2
MedPacto, Inc.
2019–2024
Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1
Principal investigator · Terminated · Phase 2
Lawrence Fong
2017–2019
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
Principal investigator · Terminated · Phase 2
Lawrence Fong
2016–2020
Neoadjuvant Atezolizumab in Localized Bladder Cancer
Principal investigator · Completed · Phase 2
Lawrence Fong
2016–2023